The size threshold that makes OATS the preferred choice

Whether microfracture will work for a given ankle lesion depends, more than on anything else, on size. Below a diameter of roughly 15 mm — or an area of 150 mm² on MRI — bone marrow stimulation reliably produces acceptable results. Above that threshold, it predictably does not.

Two landmark studies established this boundary. Chuckpaiwong et al. (2008) reviewed 105 osteochondral lesions of the talus and found no treatment failures among lesions smaller than 15 mm in average diameter; only one patient in three succeeded when the lesion exceeded that measurement. Choi et al. (2009) analysed 168 lesions and placed the MRI cut-off at 150 mm² — findings that have since become the practical dividing line in clinical decision-making.

For lesions above this threshold, and for cystic lesions regardless of measured area, OATS becomes the preferred primary strategy rather than a fallback. It is also the most commonly recommended option when marrow stimulation has already been attempted and has failed to provide lasting relief.

The biological reason matters: microfracture stimulates fibrocartilage — a mechanically inferior tissue that tends to soften over time under load. OATS transplants intact hyaline cartilage from the patient's own knee, restoring the joint surface with tissue that more closely matches what was lost. For larger, mechanically demanding defects on the weight-bearing talar dome, that distinction in tissue quality becomes the deciding clinical argument.

What OATS actually involves

The operation takes place in a single theatre visit — no staging, no cell-culture interval, no return trip to the operating table. Using a small coring tool, the surgeon removes one or more cylindrical plugs of bone and healthy cartilage from a non-weight-bearing zone of the patient's own knee — typically the outer edge of the lower femur (lateral femoral condyle) or the medial trochlea.

Those plugs are press-fitted into the prepared defect on the cartilage surface of the ankle bone, sitting flush with the surrounding joint surface. Because the transferred tissue is living hyaline cartilage — the same type that lines a normal, healthy joint — it integrates with the repair site rather than generating the mechanically weaker scar tissue that marrow stimulation produces.

For wider defects, a mosaicplasty approach uses several smaller plugs arranged to cover more surface area. The practical trade-off is that the spaces between plugs may fill with fibrocartilage rather than hyaline tissue, which is one reason single-plug OATS is generally preferred where defect geometry allows it.

Donor-site morbidity — discomfort or stiffness at the knee harvest point — is a genuine consideration that warrants an honest conversation before surgery. Published series report the overall rate as low; one mosaicplasty cohort of 32 patients did record at least one clinically meaningful decline in knee function, so recuperation at the donor knee is part of the recovery picture alongside the ankle itself.

Compared with cell-based techniques such as ACI or MACI — which require a biopsy appointment followed weeks or months later by a separate implantation procedure — OATS delivers the repair in a single operation.

What the evidence shows for large and cystic lesions

The most durable published data for primary OATS in this setting come from a 2018 retrospective series of 19 patients treated specifically for large cystic ankle lesions exceeding 150 mm² in area. At a mean follow-up of 83.9 months — nearly seven years — AOFAS scores had risen from 66.8 to 88.7 and VAS pain scores had fallen from 6.95 to 2.6, with 80% of patients rated as having excellent or good outcomes. Equally telling, cystic radiolucency had resolved completely on plain X-ray in every case, providing a structural endpoint that sits alongside the functional scores: the bone void had filled, not merely become less symptomatic.

A 2025 cohort adds a newer angle. Nineteen patients underwent OATS followed by a postoperative course of platelet-rich plasma and hyaluronic acid injections — biologics used here as adjuncts to the graft procedure, not as standalone treatments. At three-year mean follow-up, 94% achieved good-to-excellent AOFAS outcomes, and no patient reported long-term donor-site morbidity. Whether the biologic element materially improved on OATS alone cannot be confirmed from this cohort design, but the combination warrants attention as an evolving protocol.

The data across both series come from smaller observational studies rather than large randomised trials, which reflects the relative rarity of large cystic ankle lesions rather than a lack of clinical confidence in the technique. No direct randomised comparison of OATS against ACI or osteochondral allograft for ankle lesions currently exists.

Who is a good candidate — and who is not

Deciding whether OATS is the right operation involves more than scanning the ankle — a consultant will assess the whole clinical picture, and several factors outside the ankle itself carry real weight.

The strongest candidates share a common profile: a lesion larger than 150 mm² or one with cystic bone change beneath the cartilage surface, a body mass index below 40, and an age under 50. Patients who have already tried marrow stimulation without lasting benefit — and whose lesion falls above the size threshold where that approach predictably struggles — are also well-placed for OATS as a revision strategy.

The knee warrants particular attention, and the reason is specific to this procedure. The donor grafts come from the patient's own knee, so the health of that joint directly affects what the surgeon can harvest. Concurrent knee osteoarthritis above Kellgren-Lawrence grade 2 is a relative contraindication: cartilage already compromised by degenerative change is not suitable graft material. Inflammatory arthritis and prior joint infection also exclude OATS, because systemic disease or previous sepsis within the joint undermines graft integration.

Pre-existing ankle osteoarthritis — distinct from the focal defect itself — is an honest predictor of more modest results. A 2025 mosaicplasty cohort of 32 patients found that established osteoarthritis at the ankle reduced the odds of reaching an AOFAS score above 80. That does not automatically rule surgery out, but it shifts the conversation toward realistic expectations rather than optimistic projections.

Age over 50 is a soft boundary rather than a hard cut-off. Knee health, activity level, and the specific defect pattern matter more than the number alone, and individual assessment at consultation will always take precedence over any general threshold.

Surgical access and the mosaicplasty trade-off

Access to the talar dome depends on where the lesion sits, and the surgical route chosen has direct implications for recovery.

For medial talar dome lesions, a fully arthroscopic approach — burring the anterior lip of the distal tibia to create the required instrument angle — makes it possible to deliver the osteochondral graft without a medial malleolar osteotomy. A 2024 technique paper describes this single-step method specifically for its ability to eliminate the healing burden a deliberate bone cut would otherwise impose on the patient.

Centrolateral lesions present a harder access problem. When instrument angles cannot be achieved arthroscopically, an anterior chevron-type tibial osteotomy (approximately 3 cm wide, 2 cm deep, 4 cm high) can widen the working corridor. The published evidence for this route is limited to a single reported case followed to 44 months, where the patient was asymptomatic and fully active — useful as a proof of feasibility for a technically demanding access point, but not yet supported by series-level data.

When multiple plugs are used (mosaicplasty) to cover a wider defect, a quality-of-repair issue arises beyond what section two introduced: in practice, fibrocartilage filling those inter-plug gaps may not behave uniformly across the whole defect surface, and the longer-term durability of a patchwork repair differs from a single-core restoration. A 2025 prospective cohort of 32 mosaicplasty patients found that 25% required a second procedure for hardware removal — not a surgical failure, but a foreseeable eventuality that forms a routine part of the consent conversation.

Single-plug OATS sidesteps the gap problem entirely but is limited to more contained defects, making it unsuitable where only mosaicplasty can achieve adequate surface coverage.

Recovery timeline and what to expect long-term

Seven years of follow-up from the primary large-lesion series is a meaningful horizon for a cartilage procedure — functional scores and pain levels held in the good-to-excellent range throughout that period, suggesting the benefit is durable rather than a short-term gain that gradually erodes. Where post-operative PRP and hyaluronic acid injections have been added to the protocol, results at three years have been similarly encouraging, though that combination has not yet been tracked long enough to know whether those gains hold over a decade.

Precise recovery benchmarks — weeks in a boot, return-to-sport timing — are harder to pin down than the outcome scores suggest, because ankle osteochondral defects are relatively uncommon injuries. The strongest evidence comes from observational series of 19–32 patients, placing it at Level III–IV on the evidence hierarchy. How results hold across different lesion locations on the talar dome, containment patterns, and shoulder-type anatomy remains an open question the current literature has not yet closed.

What that means practically is that individual assessment carries more weight here than for better-studied procedures. Lesion location, the health of the donor knee, and any background ankle osteoarthritis all shape what outcomes are realistic for a specific patient — details that only a clinical evaluation and appropriate imaging can resolve. Assessment at MSK Doctors is available without a GP referral; further details are at mskdoctors.com.

1. [1] Long-term evaluation of Primary Osteochondral Autograft Transfer System (OATS) for large cystic type osteochondral lesion of talus. (2018). https://doi.org/10.1177/2473011418s00440 https://doi.org/10.1177/2473011418s00440
2. [2] Osteochondral Autograft Transplantation Coupled With Platelet-Rich Plasma and Hyaluronic Acid Injections Can Yield Favorable Outcomes in Patients With Osteochondral Lesions of the Talus. (2025). https://doi.org/10.1016/j.asmr.2025.101206 https://doi.org/10.1016/j.asmr.2025.101206
3. [3] Osteochondral Autograft Transplant (Mosaicplasty) Without Debriding the Recipient Site in Osteochondral Lesions of the Talus: Clinical Outcomes of a Prospective Study. (2025). https://doi.org/10.1177/10711007251393253 https://doi.org/10.1177/10711007251393253
4. [4] Anterior Chevron-type Tibial Osteotomy for Treatment of Osteochondral Lesion of the Talus Using Osteochondral Autograft Transfer System. (2025). https://doi.org/10.1097/btf.0000000000000461 https://doi.org/10.1097/btf.0000000000000461
5. [5] The Efficacy of Microfracture Combined with Extracorporeal Shock Wave Therapy and Hyaluronic Acid Injections for Treating Osteochondral Lesion of the Talus. (2025). https://doi.org/10.1053/j.jfas.2025.05.020 https://doi.org/10.1053/j.jfas.2025.05.020
6. [6] All Arthroscopic Osteochondral Autograft Transplantation for Medial Talar Dome Lesions With Burring of the Anterior Lip of the Distal Tibia. (2024). https://doi.org/10.1016/j.eats.2024.103109 https://doi.org/10.1016/j.eats.2024.103109
7. [7] Return to Sports Activity After Microfracture for Osteochondral Lesion of the Talus in Skeletally Immature Children. (2024). https://doi.org/10.1177/10711007241241067 https://doi.org/10.1177/10711007241241067